Clinical expansion Rapid Novor is actively expanding its antibody sequencing portfolio through clinical studies and disease monitoring, presenting opportunities to sell HDX-MS epitope mapping and EasyM-based disease response analytics to pharmaceutical companies, contract research organizations, and clinical trial sponsors.

Strategic partnerships Recent and ongoing collaborations with Sino Biological, PMCF, and MAbSilico indicate a receptive market for integrated service offerings; potential sales angles include bundled antibody sequencing with epitope mapping, or combined proteomics and structure-function insights for partner ecosystems.

Product leadership As a leading provider of AI-driven and mass spectrometry–based antibody sequencing, Rapid Novor can target biotech firms accelerating therapeutic antibody development, offering REmAb sequencing, WILD isobaric residue discrimination, and AI-enabled HDX-MS epitope mapping as differentiated capabilities.

Scale and reach With a global research focus and university-origin science, the company services multiple customers across academia and industry; sales opportunities exist in expanding adoption of REmAb and EasyM through CROs and translational research programs seeking scalable, routine antibody sequencing.

Market readiness Funding history and steady revenue indicate growing demand for proteomics-based solutions; leverage financial stability and demonstrated clinical study activity to position Rapid Novor as a trusted vendor for ongoing product evaluations, pilot programs, and long-term collaborations.